{"doi":"10.1002/ajh.27692","title":"Arginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial","abstract":"We present a prospective randomized, placebo-controlled trial of intravenous arginine in patients 3-21 years hospitalized with sickle cell disease vaso-occlusive pain episodes (SCD-VOE) at two tertiary-care children's hospitals. Participants were randomized into 1 of 3 arms: Standard-dose (SD; 100 mg/kg/dose) every 8 h, Loading-dose (200 mg/kg followed by SD), or Placebo. The primary outcome was total parenteral opioid use (TPO). Secondary outcomes included time-to-crisis-resolution, pain scores, patient-reported outcomes (PROs), arginine bioavailability, and biomarkers of oxidative stress/mitochondrial function. Of 1548 patients screened, 108 were randomized (36 per study-arm; mean 12.6 ± 3.8 years, 52% female, and 65% hemoglobin-SS). This study did not meet its primary endpoint. TPO, time-to-crisis-resolution, pain scores, and PROs at discharge were similar across arms. Post hoc sensitivity analyses of children 5-16 years old demonstrated nearly double TPO utilization in those receiving placebo versus arginine (n = 87, p = 0.056), achieving significance in patients with plasma arginine < 60 μM. Arginine was low at presentation in 79% of patients (mean 50 ± 28 μM), and increased with arginine therapy (p < 0.001). Arginine bioavailability at VOE presentation inversely correlated with time-to-crisis-resolution (r = -0.39, p = 0.01) after placebo, an association eliminated by arginine supplementation (r = -0.04, p = 0.70). A dose-dependent increase in platelet-mitochondrial activity occurred after arginine versus no change after placebo (p < 0.001); plasma protein-carbonyl levels, a measure of oxidative stress, decreased after arginine therapy (p < 0.001) but increased in the placebo group (p = 0.02). SCD-VOE is associated with an acquired arginine deficiency that correlates with worse clinical outcomes. Arginine improved mitochondrial function and decreased oxidative stress compared to placebo, with clinically relevant opioid-sparing becoming significant in children with the lowest arginine concentration. TRIAL REGISTRATION: Registered with ClinicalTrials.gov (NCT02536170) in August 2015.","journal":"American Journal of Hematology","year":2025,"id":517341,"datarank":0.39563081242017717,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.06604712581974422,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.06604712581974422,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":6,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9632,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02536170"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1055917,"name":"Dunia Hatabah","orcid":"0009-0006-6685-2902","position":1,"is_corresponding":false},{"id":1288953,"name":"Rawan Korman","orcid":"0009-0009-9780-9589","position":2,"is_corresponding":false},{"id":493644,"name":"Scott Gillespie","orcid":"0000-0003-1295-3602","position":3,"is_corresponding":false},{"id":380284,"name":"Nitya Bakshi","orcid":"0000-0002-0876-9506","position":4,"is_corresponding":false},{"id":333555,"name":"Lou Ann S. Brown","orcid":"0000-0002-9745-0619","position":5,"is_corresponding":false},{"id":333560,"name":"Frank Harris","orcid":"0000-0001-8697-7186","position":6,"is_corresponding":false},{"id":930315,"name":"Deborah Leake","orcid":null,"position":7,"is_corresponding":false},{"id":451033,"name":"Chris A. Rees","orcid":"0000-0001-6449-0377","position":8,"is_corresponding":false},{"id":930316,"name":"Kirshma Khemani","orcid":null,"position":9,"is_corresponding":false},{"id":308825,"name":"Elliott Vichinsky","orcid":"0000-0002-0500-9579","position":10,"is_corresponding":false},{"id":1176312,"name":"Alexus Locke","orcid":"0000-0003-4475-101X","position":11,"is_corresponding":false},{"id":1383591,"name":"Bridget Wynn","orcid":"0000-0001-9512-3465","position":12,"is_corresponding":false},{"id":454883,"name":"Mark Griffiths","orcid":"0000-0001-8612-1783","position":13,"is_corresponding":false},{"id":1109457,"name":"Hagar Wilkinson","orcid":null,"position":14,"is_corresponding":false},{"id":335427,"name":"Polly Kumari","orcid":null,"position":15,"is_corresponding":false},{"id":810274,"name":"Lisa Sudmeier","orcid":"0000-0002-4974-2713","position":16,"is_corresponding":false},{"id":106180,"name":"Sruti Shiva","orcid":"0000-0003-3535-2113","position":17,"is_corresponding":false},{"id":333557,"name":"Carlton Dampier","orcid":"0000-0002-7738-2620","position":18,"is_corresponding":false},{"id":333554,"name":"Claudia R. Morris","orcid":"0000-0001-6019-2858","position":0,"is_corresponding":true}],"reference_count":92,"raw_metadata":null,"created_at":"2026-07-19T02:48:59.410472Z","pmid":"40270092","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}